Peri-implantitisNCT05832541
Expression of Epithelial-Mesenchymal Transition Associated Markers in Peri-implant Tissues
An observational study of Peri-implantitis, run by University of Baghdad at 1 site in Iraq.
Trial summary
Peri-implantitis is an inflammation of bacterial etiology characterized by inflammation of mucous membranes and bone loss around the dental implant. A specific dental plaque bacteria could stimulate host cells, including the junctional epithelium, to secrete a range of pro-inflammatory cytokines involved in initiating… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Peri-implantitis
- How many people
- 40 participants
- Where
- 1 siteIraq
- Study dates
- 18 Aug 2022to 15 Aug 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The participants of this study will be selected from the patients' pool who will attend private clinics in Karbala and nearby governorates. The target population will be those who seek dental implant therapy. The control group will involve those who intended for replacing their missing teeth by dental implants. On the other hand, the test group will involve those diagnosed with peri-implantitis and need surgical intervention during follow-up visits
Who may be able to join
- For test group: adult patient age ≥18 years old presented having at least one dental implant with the following criteria for test group 1: (a) be in function for >12 months; (b) clinically diagnosed as peri-implantitis with probing pocket depth ≥ 6 mm, bleeding on probing and/or suppuration; (c) presence of radiographic bone loss when compared to previous radiographs or with bone loss ≥ 3 mm apical to the 1st thread of the fixture; (d) presence of visual signs of inflammation.
- For the control group: adult patient age ≥18 years old presented with: (a) one or more adjacent missing teeth in the posterior maxilla or mandible (positions premolar to molar); (b) adequate bone quality and availability for an implant placement of 4.5- 5.0 mm diameter and 8.5-13 mm length; (c) keratinized mucosa (KT) width of at least 3 mm.
- for both groups the patients give written consent to participate and attend the planned follow-up visits
Who cannot join
- For the test group: the exclusion criteria will be as follows: (a) patients with a history of chronic diseases such as diabetes mellitus; (b) currently smokers; (c) pregnant or lactating women; (d) patients who received peri-implant surgical therapy within 6 months before sampling; (e) patients who received antimicrobial therapy (systemic or local) within 3 months before sampling.
- For the control group: the exclusion criteria will be as follows: (a) medical condition contraindicating implant surgery; (b) local inflammation (including untreated periodontitis); (c) post-extraction sites with less than 6 weeks of healing; (d) persistent intraoral infection; (e) absence of keratinized tissue; (f) history of chronic diseases such as diabetes mellitus; (g) currently a smoker and former smoker
Trial locations and contacts
1 site in 1 country.
Iraq1 site, 1 recruiting
- Recruiting
Talib A. Alnajaty
Karbala, 56001
Talib A Alnajaty, 009647707905702, taleb.ali1105a@codental.uobaghdad.edu.iq
About this study
Official title: Expression of Epithelial-Mesenchymal Transition (EMT) Associated Markers in Peri-implant Tissues From Peri-implantitis Patients: A Case-Control Study
Peri-implantitis is an inflammation of bacterial etiology characterized by inflammation of mucous membranes and bone loss around the dental implant. A specific dental plaque bacteria could stimulate host cells, including the junctional epithelium, to secrete a range of pro-inflammatory cytokines involved in initiating the epithelial-mesenchymal transition (EMT) process. EMT has been described as the transdifferentiation of epithelial cells into motile mesenchymal cells.
Moreover, cytokines and bacterial products have been highlighted as EMT-predisposing factors. The EMT process could render epithelial cells to lose their cell-cell adhesion and cell polarity that lend these cells to lose their function as an integrated epithelial barrier.
Read more
E-cadherin is a calcium-dependent cell adhesion molecule that establishes cell-cell adhesion that plays a critical role in maintaining a barrier function in the human epithelium, including gingiva. The loss of E-cadherin is one of the most common biological indicators for EMT. In contrast, vimentin is an intermediate filament expressed in mesenchymal cells and is a canonical marker for EMT, which also promotes cell motility and an invasive phenotype.
It is largely reported that EMT is regulated by various transcriptional factors such as Snail Family Transcriptional Repressor SNAIL1 and SNAIL2, zinc-finger E-box-binding (ZEB)1 and ZEB2 and TWIST transcription factors that suppress epithelial marker genes, and activate genes related with the mesenchymal phenotype.
Recently, in vivo study has investigated the level of EMT markers in the gingival tissues of periodontitis patients. It was found that the expression of E-cadherin was downregulated while vimentin expression was upregulated.
Despite the similarities and differences between the pathogenesis of periodontal and peri-implant diseases, the role of dental biofilm in the etiopathogenesis of the aforementioned diseases was studied largely. While it is now accepted that EMT may potentially play a role in periodontal disease pathogenicity, the possible role of EMT in the disintegration of the peri-implant epithelial barrier and the pathogenesis of peri-implant disease has not yet been investigated.
Read the detailed description
Dental implant therapy is a reliable treatment for replacing missing or lost teeth. Despite its high survival and success rates, it has long been realized that biological complications could occur in osseointegrated implants, collectively termed peri-implant diseases. Peri-implantitis is the second most common form of peri-implant disease, and its prevalence was shown to be 10% to 30% at the implant level and 20% at the patient level.
Peri-implantitis is an inflammation of bacterial etiology characterized by inflammation of mucous membranes and bone loss around the dental implant. Clinically, it shows signs of inflammation, bleeding on probing and/or suppuration, increased probing depths, and/or recession of the mucosal margin in addition to radiographic bone loss compared to previous examinations.
Inflammatory peri-implant lesions usually start due to the accumulation of bacterial plaque and progress in a faster pattern compared to periodontitis.
It has been reported that specific dental plaque bacteria could stimulate host cells, including the junctional epithelium, to secrete a range of pro-inflammatory cytokines involved in initiating the epithelial-mesenchymal transition (EMT) process. EMT has been described as the transdifferentiation of epithelial cells into motile mesenchymal cells. It is considered integral in the development, wound healing, and stem cell behavior and contributes pathologically to fibrosis and cancer progression.
Moreover, cytokines and bacterial products have been highlighted as EMT-predisposing factors. It has been proposed that the EMT process could render epithelial cells to lose their cell-cell adhesion and cell polarity that lend these cells to lose their function as an integrated epithelial barrier. Consequently, bacterial invasion into the underlying connective tissues could occur, and epithelial cells are assumed to have a mesenchymal cell phenotype through the upregulation of mesenchymal markers and downregulation of epithelial markers.
E-cadherin is a calcium-dependent cell adhesion molecule that establishes cell-cell adhesion, known as the adherens junction, playing a critical role in maintaining a barrier function in the human epithelium, including gingiva. The loss of E-cadherin is one of the most common biological indicators for EMT. In contrast, vimentin is an intermediate filament expressed in mesenchymal cells and is a canonical marker for EMT, which also promotes cell motility and an invasive phenotype. It has been shown that the level of vimentin protein expression is significantly increased by P. gingivalis infection.
It is largely reported that EMT is regulated by various transcriptional factors such as Snail Family Transcriptional Repressor SNAIL1 and SNAIL2, zinc-finger E-box-binding (ZEB)1 and ZEB2 and TWIST transcription factors that suppress epithelial marker genes, and activate genes related with the mesenchymal phenotype. These transcriptional factors act as E-cadherin repressors and play a pivotal role in development, fibrosis, and cancer. Several signaling pathways collaborate in the beginning and advancement of EMT, and they can promote SNAIL1 expression and transforming growth factor beta.
Recently, in vivo study has investigated the level of EMT markers in the gingival tissues of periodontitis patients. It was found that the expression of E-cadherin was downregulated while vimentin expression was upregulated. Accordingly, the authors proposed that EMT may potentially play an essential role in the pathogenesis and prognosis of periodontal disease.
Much of the etiology and pathogenesis of peri-implant disease was acknowledged to be similar to periodontitis since both share many clinical and radiologic features in common for destructive inflammatory diseases. However, in contrast to periodontitis, peri-implantitis lesions show a poorer vascular supply, a lack of connective tissue encapsulation of large inflammatory cell infiltrates, and a differing cell profile with high numbers of B cells, osteoclasts, and neutrophils. This suggests that peri-implantitis has a similar aetiopathogenesis to periodontitis but also notable differences; its progression seems faster and more aggressive.
Despite these similarities and differences between the pathogenesis of periodontal and peri-implant diseases, the role of dental biofilm in the etiopathogenesis of the aforementioned diseases was studied largely. While it is now accepted that EMT may potentially play a role in periodontal disease pathogenicity, the possible role of EMT in the disintegration of the peri-implant epithelial barrier and the pathogenesis of peri-implant disease has not yet been investigated.
- Conditions
- Peri-implantitis
- Keywords
- Peri-implantitis, Peri-implant diseases, Epithelial-mesenchymal transition, E-cadherin, Vimentin
- Medical subject headings
- Peri-Implantitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Test group (peri-implantitis) | peri-implant tissue specimen will be taken after identification of diseased interproximal implant sites. Following local anesthesia specimen will be taken either by supracrestal incision to remove all diseased soft tissue surrounding the implant or by making 2 parallel incisions, 4 mm apart, with a 15C scalpel blade through the soft tissue until bone contact would be achieved. The 2 incisions will be connected with a perpendicular incision that will be placed at a distance of 4 mm from the proximal surface of implant. The biopsies, including the entire supracrestal soft tissue portion of the diseased site, will be carefully retrieved and prepared for histopathological and immunohistochemical analysis | |
| Control group (clinically healthy) | tissue sample for control group will be collected from patients undergoing implant surgery. After local anesthesia, a crystal incision will be performed, and a full-thickness flap will be elevated. Following the osteotomy, one or more implants of 4.5-5.0 mm in diameter will be placed. A narrow diameter healing abutment will be screwed in with an insertion torque > 20 NM., and flaps will be repositioned and sutured to obtain optimal adaptation of the mucosa to the titanium abutment. Sample harvesting will be done after 2 months of healing using circular punch of 4.5-5.0 mm diameter or performing a circular incision by surgical blade by which a 1.5 mm thick collar of peri-implant soft tissue will be harvested and prepared for histopathological and immunohistochemical analysis. A new 4.5-5.0 mm-wide smooth-surfaced healing abutment will be connected to the implant directly after the biopsy sampling. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peri-implant probing pocket depth (PPD)
PPD is the distance (in mm) measured from the Peri-implant mucosal margin to the base of the peri-implant sulcus/ pocket measured by using a periodontal probe, recorded at six sites per implant namely; mesio-facial, mid-facial, disto-facial, mesio-oral, mid-oral and disto-oral.
Measured: Measured at baseline just before performing peri-implant tissue harvesting.
Radiographic bone level (RBL)
RBL is the distance (in mm) measured by periapical digital radiograph using the long-cone parallel technique from the implant platform to the radiographic bone level.
Measured: Measured at baseline just before performing peri-implant tissue harvesting.
Immunohistochemical expression of EMT-related markers
Immunohistochemical expressions of two EMT-related markers (E-cadherin and vimentin) in peri-implant soft tissue samples collected from patients with peri-implantitis and healthy peri-implant tissue will be measured.
Measured: Measured at baseline
Secondary outcomes (2)
Immunohistochemical expression EMT transcriptional factor
The expression of the EMT transcriptional factor (Snail-1) in peri-implant soft tissue samples collected from patients with peri-implantitis and healthy peri-implant tissue will be measured.
Measured: Measured at baseline
Bleeding on probing (BOP)
BOP is measured by inserting a periodontal probe to the bottom of the peri-implant sulcus/ pocket with gentle movement around the implant surface. If bleeding occurs within 30 seconds after probing, the site is given a score (1), and a negative score (0) for the non-bleeding site. BOP is recorded at six sites per implant namely; mesio-facial, mid-facial, disto-facial, mesio-oral, mid-oral, disto-oral.
Measured: Measured at baseline just before performing peri-implant tissue harvesting.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2023
- Study start18 Aug 2022
- Primary completionAug 2024 (estimated)
- Study completion15 Aug 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peri-implantitisStudies of the same condition, open and under way.
- More trials run by University of BaghdadThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Baghdad
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Talib Ali Karam Alnajaty, University of Baghdad
- Investigators
- Talib A Alnajaty, Principal investigator, University of Baghdad
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05832541
- Sponsor's protocol ID
- 535622
- Status last verified
- Aug 2024
- First submitted
- 22 Mar 2023
- Last updated
- 20 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expression of Epithelial-Mesenchymal Transition (EMT) Associated Markers in Peri-implant Tissues From Peri-implantitis Patients: A Case-Control Study
- ClinicalTrials.gov ID
- NCT05832541
- Acronym / sponsor ID
- 535622
- Conditions
- Peri-implantitis
- Keywords
- Peri-implantitis, Peri-implant diseases, Epithelial-mesenchymal transition, E-cadherin, Vimentin
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University of BaghdadUniversity, hospital or other
- Study start
- 18 Aug 2022 (actual)
- Primary completion
- Aug 2024 (estimated)
- Study completion
- 15 Aug 2024 (estimated)
- First posted
- 27 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Peri-implantitis is an inflammation of bacterial etiology characterized by inflammation of mucous membranes and bone loss around the dental implant. A specific dental plaque bacteria could stimulate host cells, including the junctional epithelium, to secrete a range of pro-inflammatory cytokines involved in initiating the epithelial-mesenchymal transition (EMT) process. EMT has been described as the transdifferentiation of epithelial cells into motile mesenchymal cells.
Moreover, cytokines and bacterial products have been highlighted as EMT-predisposing factors. The EMT process could render epithelial cells to lose their cell-cell adhesion and cell polarity that lend these cells to lose their function as an integrated epithelial barrier.
E-cadherin is a calcium-dependent cell adhesion molecule that establishes cell-cell adhesion that plays a critical role in maintaining a barrier function in the human epithelium, including gingiva. The loss of E-cadherin is one of the most common biological indicators for EMT. In contrast, vimentin is an intermediate filament expressed in mesenchymal cells and is a canonical marker for EMT, which also promotes cell motility and an invasive phenotype.
It is largely reported that EMT is regulated by various transcriptional factors such as Snail Family Transcriptional Repressor SNAIL1 and SNAIL2, zinc-finger E-box-binding (ZEB)1 and ZEB2 and TWIST transcription factors that suppress epithelial marker genes, and activate genes related with the mesenchymal phenotype.
Recently, in vivo study has investigated the level of EMT markers in the gingival tissues of periodontitis patients. It was found that the expression of E-cadherin was downregulated while vimentin expression was upregulated.
Despite the similarities and differences between the pathogenesis of periodontal and peri-implant diseases, the role of dental biofilm in the etiopathogenesis of the aforementioned diseases was studied largely. While it is now accepted that EMT may potentially play a role in periodontal disease pathogenicity, the possible role of EMT in the disintegration of the peri-implant epithelial barrier and the pathogenesis of peri-implant disease has not yet been investigated.
Detailed description
Dental implant therapy is a reliable treatment for replacing missing or lost teeth. Despite its high survival and success rates, it has long been realized that biological complications could occur in osseointegrated implants, collectively termed peri-implant diseases. Peri-implantitis is the second most common form of peri-implant disease, and its prevalence was shown to be 10% to 30% at the implant level and 20% at the patient level.
Peri-implantitis is an inflammation of bacterial etiology characterized by inflammation of mucous membranes and bone loss around the dental implant. Clinically, it shows signs of inflammation, bleeding on probing and/or suppuration, increased probing depths, and/or recession of the mucosal margin in addition to radiographic bone loss compared to previous examinations.
Inflammatory peri-implant lesions usually start due to the accumulation of bacterial plaque and progress in a faster pattern compared to periodontitis.
It has been reported that specific dental plaque bacteria could stimulate host cells, including the junctional epithelium, to secrete a range of pro-inflammatory cytokines involved in initiating the epithelial-mesenchymal transition (EMT) process. EMT has been described as the transdifferentiation of epithelial cells into motile mesenchymal cells. It is considered integral in the development, wound healing, and stem cell behavior and contributes pathologically to fibrosis and cancer progression.
Moreover, cytokines and bacterial products have been highlighted as EMT-predisposing factors. It has been proposed that the EMT process could render epithelial cells to lose their cell-cell adhesion and cell polarity that lend these cells to lose their function as an integrated epithelial barrier. Consequently, bacterial invasion into the underlying connective tissues could occur, and epithelial cells are assumed to have a mesenchymal cell phenotype through the upregulation of mesenchymal markers and downregulation of epithelial markers.
E-cadherin is a calcium-dependent cell adhesion molecule that establishes cell-cell adhesion, known as the adherens junction, playing a critical role in maintaining a barrier function in the human epithelium, including gingiva. The loss of E-cadherin is one of the most common biological indicators for EMT. In contrast, vimentin is an intermediate filament expressed in mesenchymal cells and is a canonical marker for EMT, which also promotes cell motility and an invasive phenotype. It has been shown that the level of vimentin protein expression is significantly increased by P. gingivalis infection.
It is largely reported that EMT is regulated by various transcriptional factors such as Snail Family Transcriptional Repressor SNAIL1 and SNAIL2, zinc-finger E-box-binding (ZEB)1 and ZEB2 and TWIST transcription factors that suppress epithelial marker genes, and activate genes related with the mesenchymal phenotype. These transcriptional factors act as E-cadherin repressors and play a pivotal role in development, fibrosis, and cancer. Several signaling pathways collaborate in the beginning and advancement of EMT, and they can promote SNAIL1 expression and transforming growth factor beta.
Recently, in vivo study has investigated the level of EMT markers in the gingival tissues of periodontitis patients. It was found that the expression of E-cadherin was downregulated while vimentin expression was upregulated. Accordingly, the authors proposed that EMT may potentially play an essential role in the pathogenesis and prognosis of periodontal disease.
Much of the etiology and pathogenesis of peri-implant disease was acknowledged to be similar to periodontitis since both share many clinical and radiologic features in common for destructive inflammatory diseases. However, in contrast to periodontitis, peri-implantitis lesions show a poorer vascular supply, a lack of connective tissue encapsulation of large inflammatory cell infiltrates, and a differing cell profile with high numbers of B cells, osteoclasts, and neutrophils. This suggests that peri-implantitis has a similar aetiopathogenesis to periodontitis but also notable differences; its progression seems faster and more aggressive.
Despite these similarities and differences between the pathogenesis of periodontal and peri-implant diseases, the role of dental biofilm in the etiopathogenesis of the aforementioned diseases was studied largely. While it is now accepted that EMT may potentially play a role in periodontal disease pathogenicity, the possible role of EMT in the disintegration of the peri-implant epithelial barrier and the pathogenesis of peri-implant disease has not yet been investigated.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test group (peri-implantitis) | – | –peri-implant tissue specimen will be taken after identification of diseased interproximal implant sites. Following local anesthesia specimen will be taken either by supracrestal incision to remove all diseased soft tissue surrounding the implant or by making 2 parallel incisions, 4 mm apart, with a 15C scalpel blade through the soft tissue until bone contact would be achieved. The 2 incisions will be connected with a perpendicular incision that will be placed at a distance of 4 mm from the proximal surface of implant. The biopsies, including the entire supracrestal soft tissue portion of the diseased site, will be carefully retrieved and prepared for histopathological and immunohistochemical analysis |
| Control group (clinically healthy) | – | –tissue sample for control group will be collected from patients undergoing implant surgery. After local anesthesia, a crystal incision will be performed, and a full-thickness flap will be elevated. Following the osteotomy, one or more implants of 4.5-5.0 mm in diameter will be placed. A narrow diameter healing abutment will be screwed in with an insertion torque > 20 NM., and flaps will be repositioned and sutured to obtain optimal adaptation of the mucosa to the titanium abutment. Sample harvesting will be done after 2 months of healing using circular punch of 4.5-5.0 mm diameter or performing a circular incision by surgical blade by which a 1.5 mm thick collar of peri-implant soft tissue will be harvested and prepared for histopathological and immunohistochemical analysis. A new 4.5-5.0 mm-wide smooth-surfaced healing abutment will be connected to the implant directly after the biopsy sampling. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The participants of this study will be selected from the patients' pool who will attend private clinics in Karbala and nearby governorates. The target population will be those who seek dental implant therapy. The control group will involve those who intended for replacing their missing teeth by dental implants. On the other hand, the test group will involve those diagnosed with peri-implantitis and need surgical intervention during follow-up visits
Key inclusion criteria (3 listed)
- For test group: adult patient age ≥18 years old presented having at least one dental implant with the following criteria for test group 1: (a) be in function for >12 months; (b) clinically diagnosed as peri-implantitis with probing pocket depth ≥ 6 mm, bleeding on probing and/or suppuration; (c) presence of radiographic bone loss when compared to previous radiographs or with bone loss ≥ 3 mm apical to the 1st thread of the fixture; (d) presence of visual signs of inflammation.
- For the control group: adult patient age ≥18 years old presented with: (a) one or more adjacent missing teeth in the posterior maxilla or mandible (positions premolar to molar); (b) adequate bone quality and availability for an implant placement of 4.5- 5.0 mm diameter and 8.5-13 mm length; (c) keratinized mucosa (KT) width of at least 3 mm.
- for both groups the patients give written consent to participate and attend the planned follow-up visits
Key exclusion criteria (2 listed)
- For the test group: the exclusion criteria will be as follows: (a) patients with a history of chronic diseases such as diabetes mellitus; (b) currently smokers; (c) pregnant or lactating women; (d) patients who received peri-implant surgical therapy within 6 months before sampling; (e) patients who received antimicrobial therapy (systemic or local) within 3 months before sampling.
- For the control group: the exclusion criteria will be as follows: (a) medical condition contraindicating implant surgery; (b) local inflammation (including untreated periodontitis); (c) post-extraction sites with less than 6 weeks of healing; (d) persistent intraoral infection; (e) absence of keratinized tissue; (f) history of chronic diseases such as diabetes mellitus; (g) currently a smoker and former smoker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Peri-implant probing pocket depth (PPD)
Time frame: Measured at baseline just before performing peri-implant tissue harvesting.
PPD is the distance (in mm) measured from the Peri-implant mucosal margin to the base of the peri-implant sulcus/ pocket measured by using a periodontal probe, recorded at six sites per implant namely; mesio-facial, mid-facial, disto-facial, mesio-oral, mid-oral and disto-oral.
Radiographic bone level (RBL)
Time frame: Measured at baseline just before performing peri-implant tissue harvesting.
RBL is the distance (in mm) measured by periapical digital radiograph using the long-cone parallel technique from the implant platform to the radiographic bone level.
Immunohistochemical expression of EMT-related markers
Time frame: Measured at baseline
Immunohistochemical expressions of two EMT-related markers (E-cadherin and vimentin) in peri-implant soft tissue samples collected from patients with peri-implantitis and healthy peri-implant tissue will be measured.
2 secondary outcomes
Immunohistochemical expression EMT transcriptional factor
Time frame: Measured at baseline
Bleeding on probing (BOP)
Time frame: Measured at baseline just before performing peri-implant tissue harvesting.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Peri-implantitis
Not yet recruiting
Effect of Customized Versus Stock Healing Abutments on Peri-Implant Soft Tissue
Peri-Implantitis
RecruitingObservational study
Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid
Peri Implantitis, Peri Implant Mucositis
Not yet recruitingObservational study
Diagnostic Accuracy of Large Language Models for Peri-Implant Marginal Bone Loss on Panoramic Radiographs
Peri-implantitis, Alveolar Bone Loss
RecruitingObservational study
Access to Probing and Peri-implant Diseases
Peri-implantitis, Peri-implant Bone Loss
Not yet recruitingObservational study
ATR-FTIR and Raman Spectroscopy of Peri-Implant Crevicular Fluid in Peri-Implantitis
Peri-Implantitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Talib A Alnajaty principal investigator
University of Baghdad
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Peri-implantitis, run by University of Baghdad at 1 site in Iraq.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Talib A Alnajaty (009647707905702, taleb.ali1105a@codental.uobaghdad.edu.iq), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peri-implant probing pocket depth (PPD) (time frame: Measured at baseline just before performing peri-implant tissue harvesting.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2024.